Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial |
| |
| Authors: | Larry R Jackson MD II Jonathan P Piccini MD MHSc Derek D Cyr PhD Matthew T Roe MD MHS Megan L Neely PhD Felipe Martinez MD Thomas F Lüscher MD Renato D Lopes MD PhD MHS Kenneth J Winters MD Harvey D White MB ChB DSc Paul W Armstrong MD Keith AA Fox MB ChB Dorairaj Prabhakaran MD DM MSc Deepak L Bhatt MD MPH E Magnus Ohman MD Ramón Corbalán MD |
| |
| Institution: | 1. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina;2. Duke Clinical Research Institute, Durham, North Carolina;3. Department of Cardiology, Córdoba National University, Córdoba, Argentina;4. University Heart Center, Cardiology, University Hospital Zurich, Zurich, Switzerland;5. Department of Research and Development, Research Cardiologist, Indianapolis, Indiana;6. Eli Lilly and Company, Indianapolis, Indiana;7. Green Lane Cardiovascular Service, Department of Medicine, Division of Cardiology, Auckland, New Zealand;8. Auckland City Hospital, Auckland, New Zealand;9. Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta;10. Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom;11. Centre for Chronic Disease Control and Public Health Foundation of India, New Delhi, India;12. Division of Cardiology, Department of Medicine, Boston, Massachusetts;13. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts;14. Department of Medicine, Division of Cardiology, Santiago, Chile;15. Pontificia Universidad Católica de Chile, Santiago, Chile |
| |
| Abstract: | Associations between atrial fibrillation (AF), outcomes, and response to antiplatelet therapies in patients with acute coronary syndrome (ACS) managed medically without revascularization remain uncertain. We examined these associations for medically managed ACS patients randomized to dual antiplatelet therapy (DAPT) using patient data from the TRILOGY ACS trial. DAPT included aspirin plus clopidogrel 75 mg/d or prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years). Patients receiving oral anticoagulants were excluded. Cox proportional hazards regression modeling was used to characterize associations between patients with AF (AF+) vs those without (AF?) and risk of ischemic and bleeding events, and to explore effects of randomized treatment on outcomes. Among 9101 patients with baseline AF status, 710 (7.8%) had AF. AF+ patients were older and had more comorbidities. Unadjusted associations of the composite of cardiovascular death/myocardial infarction/stroke were significantly higher among AF patients at 30 months (31.1% vs 18.4%; HR: 1.61, 95% CI: 1.35‐1.92, P < 0.001), but differences did not persist after adjustment (HR: 1.16, 95% CI: 0.97‐1.39, P = 0.11). When individual components of the composite endpoint were evaluated, 30‐month risk of events in AF+ patients was significantly higher. Thirty‐month risk of all‐cause death was significantly higher in AF+ patients: 18.1% vs 11.1% (HR: 1.62, 95% CI: 1.30‐2.02, P < 0.001). There was no significant interaction with randomized treatment and AF for the primary endpoint. Among medically managed high‐risk ACS patients receiving DAPT, AF was associated with higher unadjusted risks of ischemic and bleeding outcomes that were similar by treatment group. |
| |
| Keywords: | |
|
|
